ArticleQuantitative imaging in medicine and surgery2026
The impact of FAPI PET on staging and management in patients with digestive system tumors: a systematic review and meta-analysis.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fibroblast Activation Protein-Targeted Radioligand Therapy (FAP RLT) in Gastroenteropancreatic Malignancies: Biological Rationale, Clinical Evidence, and Future Directions.World journal of nuclear medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recent studies have reported the excellent diagnostic performance of fibroblast-activated protein inhibitor (FAPI) positron emission tomography (PET) in patients with digestive system tumors. We performed a systematic review and meta-analysis to investigate the impact of FAPI PET on staging and management changes in those patients and to further elucidate the important role of FAPI PET in clinical practice. Methods: A thorough literature search was performed in PubMed, EMBASE, MEDLINE, and Scopus databases until May 31, 2024, for eligible studies regarding the impact of FAPI PET on staging and management in patients with digestive system tumors. Quality assessment was performed using Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) and QUADAS-comparative (QUADAS-C). The proportions of changes were pooled using a random- or fixed-effect model according to the heterogeneity. Sub-group analyses were utilized to explore heterogeneity. Results: We included 13 studies in the systematic review and 11 studies encompassing 492 patients for meta-analysis. The pooled proportions of staging and management changes were 26% [95% confidence interval (95% CI): 21-32%; I Conclusions: FAPI PET can significantly alter the staging and management plan in patients with digestive system tumors. Further prospective studies are warranted to evaluate the impact of FAPI PET on staging and management changes for certain types of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.